Dr. Reddy’s Laboratories Launches Versavo (biosimilar, bevacizumab) for Multiple Cancer Indications in India

 Dr. Reddy’s Laboratories Launches Versavo (biosimilar, bevacizumab) for Multiple Cancer Indications in India

Dr. Reddy’s Laboratories Launches Versavo (biosimilar, bevacizumab) for Multiple Cancers in India

Shots:

  • Dr. Reddy’s has launched Versavo (bevacizumab), a biosimilar of Roche’s Avastin in 100mg and 400mg single use vials for the treatment of multiple cancers including m-colorectal cancer, NSCLC, recurrent glioblastoma, m-RCC, cervical cancer, m-breast cancer, epithelial ovarian, fallopian tube and primary peritoneal cancer
  • The launch of Versavo will strengthen Dr. Reddy’s oncology portfolio and will address the need of patients with different cancer in India
  • Versavo is a mAb, act by inhibiting the VEGF activity. Dr. Reddy’s has six biosimilar products commercialized in India and in other emerging markets from its biosimilar portfolio of oncology and immunology

Click here to­ read full press release/ article | Ref: Dr.Reddy’s Laboratories | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post